### Efficacy Trial

#### Vaginal Ring

**Dapivirine Ring (Monthly)**
- Planned
- FDA approval for adults and adolescents who do not have receptive vaginal sex

**Oral PrEP**

**F/TAF (Daily pill)**
- DISCOVER
- Randomized controlled trial of once-daily F/TAF; ongoing in 5,400 MSM & transgender women in Austria, Canada, Denmark, France, Germany, Ireland, Italy, Netherlands, Spain, UK, US

**Islatravir (Monthly pill)**
- Impower-22
- Randomized controlled trial of monthly islatravir; ongoing in 4,500 women in the US

**Long-Acting Injectable**

**Cabotegravir (Every two months)**
- HPTN 083
- Randomized controlled trial of injectable cabotegravir every two months; ongoing in 4,500 MSM and transgender women in Argentina, Brazil, Peru, South Africa, Thailand, US, Vietnam

**Lenacapavir (Every six months)**
- HPTN 084
- Randomized controlled trial of injectable lenacapavir every two months; ongoing in 3,200 women in Botswana, Kenya, Malawi, South Africa, Uganda, Zimbabwe

**Preventive HIV Vaccine**

**ALVAC/gp120 w/MF59**
- HVTN 702
- Randomized controlled trial of ALVAC/gp120 prime-boost with MF59 adjuvant, six doses over 18 months; 5,400 men and women in South Africa; immunizations halted for non-efficacy; follow-up ongoing

**Ad26/gp140 boost**
- Imbokodo (HVTN 705/ HPX2008)
- Randomized controlled trial of Ad26 prime with gp140 boost; four doses over 12 months; fully enrolled 2,600 women in Malawi, Mozambique, South Africa, Zambia, Zimbabwe

**Ad26/clade C gp140 & mosaic gp140 boost**
- Mosaic (HVTN 706/ HPX3002)
- Randomized controlled trial of Ad26 prime with clade C and mosaic gp140 boost; ongoing in 3,800 MSM and transgender people in Argentina, Brazil, Italy, Mexico, Peru, Poland, Spain, US

**Oral PrEP and vaccine**

**PrEPVacc**
- Randomized controlled trial of DNA-MVA-env or DNA-env with F/TAF or F/TDF, planned in 1668 participants in Mozambique, South Africa, Tanzania, Uganda

**Antibody**

**VR01**
- Randomized controlled trial of the VR01 antibody infused every two months; ongoing in 2,700 MSM and transgender men & women in Brazil, Peru, Switzerland, US

**AMP (HVTN 703/ HPTN 081)**
- Randomized controlled trial of the VR01 antibody infused every two months; ongoing in 1,900 women in Botswana, Kenya, Malawi, Mozambique, Tanzania, South Africa, Zimbabwe